I'm not worried about this. The key thing to remember is that the big pharma companies might promise each other to stand together against NNVC and then one of them will betray the others. Combinations don't last without the aid of government provisions to protect them.
There are many ways a pharma can gain by doing a deal with NNVC. And NNVC will not have to take an offer that is not truly beneficial to NNVC.
We are moving forward in two fronts, the US FDA and the PHE (Europe). I think it was nanopatent who said that if not here in the US, it will be there, in Europe. I think we have good people, companies with vested reputations, in the success to the clinical trials. We also have two candidates, FluCide and DengueCide, with unprecedented and consistent test data results in efficacy (pre-IND) and now we know they have "low toxicity". I find that if anything, "Big Pharma" is trying to figure out how much will they agree to pay for licenses or acquisition, IMHO. Anticipation will build and the pps will climb.
News 
Market Data 
Discover 
